GLOBAL ETHICAL PHARMACEUTICALS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Key Developments

• In November 2023, AstraZeneca, a biopharmaceutical company, announced that Truqap (capivasertib) in combination with Faslodex (fulvestrant) is now approved in the U.S. for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more biomarker alterations.
• In October 2023, Pfizer Inc., a biopharmaceutical company, announced that the U.S. has approved VELSIPITY (etrasimod), an oral, once-daily, selective sphingosine-1-phosphate (S1P) receptor modulator for people with moderately to severely active ulcerative colitis. The approved recommended dose of VELSIPITY is 2 mg.
• In February 2023, the U.S. FDA approved ALTUVIIIO [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl], formerly known as efanesoctocog alfa, a first-in-class, high-sustained factor VIII replacement therapy. ALTUVIIIO is recommended for routine prophylaxis and on-demand treatment to control bleeding episodes, as well as perioperative care (surgery) in adults and children with hemophilia A.
• In November 2020, com, Inc., an online pharmacy store, launched two new pharmacy options to assist customers in purchasing their prescription prescriptions. Amazon pharmaceutical, a new Amazon store, enables users to conduct their pharmaceutical transactions on their desktop or mobile device via the Amazon App. Customers can use a secure pharmacy profile to input insurance information, manage prescriptions, and select payment methods before checking out.